tiprankstipranks
Advertisement
Advertisement
Spyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term Study
PremiumCompany AnnouncementsSpyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term Study
1M ago
Spyre Therapeutics price target raised to $100 from $80 at Wedbush
Premium
The Fly
Spyre Therapeutics price target raised to $100 from $80 at Wedbush
1M ago
Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target
Premium
Ratings
Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target
1M ago
Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank
PremiumThe FlySpyre Therapeutics price target raised to $115 from $102 at Deutsche Bank
2M ago
Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072
Premium
The Fly
Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072
2M ago
Spyre Expands SPY003 Rights Beyond Inflammatory Bowel Disease
Premium
Company Announcements
Spyre Expands SPY003 Rights Beyond Inflammatory Bowel Disease
2M ago
Spyre Therapeutics price target raised to $107 from $92 at Stifel
PremiumThe FlySpyre Therapeutics price target raised to $107 from $92 at Stifel
3M ago
Julian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
Premium
Ratings
Julian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
3M ago
Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders
Premium
Company Announcements
Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100